Chemical Sciences Seminars
Targeted Prodrugs to Manipulate Copper Biology of Prostate Cancer
by Dr. Subha Bhaktavatsalam (RIKEN, Japan)
Friday, September 13, 2019 from to (Asia/Kolkata)
Cancer cells have considerably different metallome than normal cells. Especially prostate cancer has been shown to overexpress several important copper trafficking proteins and recruit high levels of copper, making it more sensitive towards drugs like disulfiram.1 Disulfiram acts by altering the copper biology of prostate cancer. Though disulfiram is a promising anticancer agent, the off-target activities lead to adverse side effects.2 Disulfiram’s off-target effects can be mitigated in the cancer setting by chemical modification of the active pharmacophore, dithiocarbamate, in ways that target it preferentially to prostate cancer cells.3 In this seminar, I will present the design, development, and activity of dithiocarbamate prodrug, a Cu prochelator, that is activated in the prostate cancer microenvironment specifically.